Biomarkers in heart failure

Heart

Volumn 96, Issue 4, 2010, Pages 314-320

  Chen, Wei Chung ^a   Tran, Kimberly D ^a   Maisel, Alan S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NESIRITIDE; SPIRONOLACTONE; TROPONIN;

ACUTE HEART FAILURE; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; HUMAN; KIDNEY FUNCTION; OBESITY; OUTPATIENT CARE; PRIORITY JOURNAL;

AMBULATORY CARE; BIOLOGICAL MARKERS; HEART FAILURE; HOSPITALIZATION; HUMANS; OBESITY; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; TROPONIN;

EID: 77649143658     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.151639     Document Type: Article

References (24)

1. Krumholz HM, Wang Y, Parent EM, et al. Quality of care for elderly patients hospitalized with heart failure. Arch intern Med 1997;157:2242-7.
2. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68.
3. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-Type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. First article that truly examined the diagnostic potential of B-type natriuretic peptide in patients with heart failure.
4. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-Terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. J Am Coll Cardiol 2005;95:948-54. Key article demonstrating the importance of incorporating NT-proBNP values in the diagnosis of heart failure in dyspnoeic patients.
5. Maisel A, Hollander JE, Guss D, et al. Primary results of the rapid emergency department heart failure outpatient trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44:1328-33. Valuable article that fully explores the prognostic potential of B-type natriuretic peptide.
6. Januzzi JL Jr, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the international collaborative of NT-proBNP study. Eur Heart J 2006;27:330-7. Important article indicating the prognostic capabilities of NT-proBNP in the management of patients with heart failure.
7. Troughton RW, Prior DL, Pereira JJ, et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004;43:416-22.
8. Mohammed AA, Januzzi JL Jr. Natriuretic peptide guided heart failure management. Curr Clin Pharmacol 2009;4:87-94. Very clear and useful article to guide clinicians in the management of heart failure patients using natriuretic peptide values.
9. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733-9.
10. Maisel AS. Use of BNP levels in monitoring hospitalized heart failure patients with heart failure. Heart Fail Rev 2003;8:339-44.
11. Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004;6:301-8.
12. Bettencourt P, Ferreira S, Azevedo A, et al. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med 2002;113:215-9.
13. Mueller C, Schoeler A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
14. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
15. Shah MR, Claise KA, Bowers MT, et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: Brain Natriuretic Peptide Versus the Clinical Congestion Score (STARBRITE) trial. Am Heart J 2005;150:893-8.
16. Anwaruddin A, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal Pro-Brain Natriuretic Peptide. J Am Coll Cardiol 2006;48:1060-1.
17. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-79.
18. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-Type Natriuretic Peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5.
19. Van Kimmenade RRJ, Pinto YM, Bayes-Genis A, et al. Usefulness of intermediate amino-terminal pro-Brain Natriuretic Peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006;98:386-90.
20. Peacock WF, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117- 26. Key article showing that the measurement of troponin concentrations can add valuable information to the prognosis of patients with acute decompensated heart failure.
21. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea. J Am Coll Cardiol 2007;50:607-13.
22. Maisel A. Biomarkers in the assessment of congestive heart failure: a multi-national trial examining acute shortness of breath, heart failure, and a novel panel of biomarkers. In: Presented at European Society of Cardiology - Munich 2009.
23. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of Amino-Terminal Pro-Brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24. One of the few articles that provide evidence of the prognostic potential of galectin-3 for the evaluation of patients with acute heart failure.
24. Kempf T, von Haehling S, Peter T, et al. Prognostic utility of Growth Differentiation Factor-15 patients with chronic heart failure. J Am Coll Cardiol 2007;50:1054-60.